Migraine prevention drug trial in kids halted early
NCT ID NCT04050293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called SPN-538 to prevent migraines in children aged 6 to 11. The trial was a randomized, double-blind, placebo-controlled study, meaning some children got the drug and some got a placebo. However, the study was terminated early and only enrolled 26 participants, so we cannot draw firm conclusions about its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SPN-538 (a drug to prevent migraines)
- What this could lead to
- If it worked, this could offer a new option to reduce migraine frequency in young children.
- What could go wrong
- The trial was terminated early with very few participants, so results are limited and may not be reliable. It is unclear if SPN-538 is safe or effective for this age group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEADACHE DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CNS Healthcare
Memphis, Tennessee, 38119, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted botox shot quiet the Brain's pain center for chronic migraine?
- Could a symptom registry unmask hidden migraine variants?
- Melatonin may double up against childhood migraines
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Online sleep therapy may ease migraines in teens
- Scientists aim to forecast migraine pain using wearable sensors and early symptoms